TKMR Share Price

Open 3.80 Change Price %
High 3.85 1 Day 0.05 1.33
Low 3.72 1 Week 0.25 7.04
Close 3.80 1 Month 0.45 13.43
Volume 53215 1 Year 0.44 13.10
52 Week High 4.49
52 Week Low 2.35
TKMR Important Levels
Resistance 2 3.92
Resistance 1 3.87
Pivot 3.79
Support 1 3.73
Support 2 3.68
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
DCTH 0.16 -33.33%
FTR 1.22 8.93%
FTR 1.22 8.93%
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
More..
NASDAQ USA Top Gainers Stocks
OPXAW 0.12 200.00%
AVEO 1.25 71.23%
LOCM 0.09 50.00%
MYRX 0.09 50.00%
SNCR 16.24 33.33%
QUIK 1.60 31.15%
WRES 0.09 28.57%
IIN 8.35 27.48%
IIN 8.35 27.48%
IIN 8.35 27.48%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
TOPS 0.80 -66.67%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
SPIR 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Tekmira Pharmaceuticals Corp (NASDAQ: TKMR)

TKMR Technical Analysis 4
As on 23rd Jun 2017 TKMR Share Price closed @ 3.80 and we RECOMMEND Buy for LONG-TERM with Stoploss of 3.22 & Strong Buy for SHORT-TERM with Stoploss of 3.43 we also expect STOCK to react on Following IMPORTANT LEVELS.
TKMR Target for June
1st Target up-side 3.75
2nd Target up-side 4
3rd Target up-side 4.25
1st Target down-side 3.05
2nd Target down-side 2.8
3rd Target down-side 2.55
TKMR Other Details
Segment EQ
Market Capital 59253228.00
Sector Consumer Durables Major Pharmaceuticals
Industry
Offical website
TKMR Address
TKMR
N/A
TKMR Latest News
Mackenzie Financial Corp Holds Stake in Arbutus Biopharma Corporation (ABUS)   BNB Daily (blog)   - 25th Jun 17
Arbutus Biopharma's (ABUS) CEO Mark Murray on Q1 2017 Results - Earnings Call ...   Seeking Alpha   - 05th May 17
Arbutus Biopharma: 2 Ways For Shareholders To Win   Seeking Alpha   - 05th Apr 17
Arbutus Biopharma's (ABUS) CEO Mark Murray on Full Year 2016 Results ...   Seeking Alpha   - 22nd Mar 17
Arbutus Biopharma and Alexion in new licensing deal   Seeking Alpha   - 17th Mar 17
Arbutus Biopharma Corporation Is Poised To Catch Up In The Hepatitis B Race   Seeking Alpha   - 18th Nov 16
Arbutus Slides Following Poor Results In Hep B   Seeking Alpha   - 04th Oct 16
Arbutus Biopharma Is Currently In Second Place In The Race For An HBV Cure   Seeking Alpha   - 14th Jan 16
News Arbutus Biopharma Corp.ABUS   Wall Street Journal   - 07th Aug 15
3.80   MarketWatch   - 29th Dec 13
Interactive Technical Analysis Chart Tekmira Pharmaceuticals Corp ( TKMR NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Tekmira Pharmaceuticals Corp
TKMR Business Profile
Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing ribonucleic acid (RNA) interference (RNAi) therapeutics and providing its lipid nanoparticle (LNP) delivery technology to pharmaceutical partners. On March 1, 2012, it announced that the Company had secured a license from Alnylam to develop TKMALDH2, an RNAi therapeutic that utilizes Tekmira's LNP for the treatment of Alcohol Dependence (AD). Its lead oncology product candidate, TKM-PLK1, targets PLK1, a protein involved in tumor cell proliferation and a validated oncology target. On February 8, 2012, it announced that Phase I clinical trial for TKM-Ebola had been initiated. The Phase 1 TKM-Ebola clinical trial is a placebo-controlled, single-blind, single-ascending dose study with additional multiple-ascending dose cohorts in healthy human volunteers. In the field of RNAi therapeutics, the Company has licensed its LNP delivery technology to Alnylam Pharmaceuticals, Inc. and Merck & Co., Inc.